schliessen

Filtern

 

Bibliotheken

FH535 inhibits the proliferation of HepG2 cells via downregulation of the Wnt/β-catenin signaling pathway

Hepatocellular carcinoma (HCC) is a primary cancer of the liver. Target therapy may improve prognosis of HCC. In the present study, we evaluated the inhibition of the Wnt/β-catenin pathway as a potential therapeutic approach. HepG2 cells were treated with the β-catenin inhibitor FH535. β-catenin pro... Full description

Journal Title: Molecular Medicine Reports 4/2014, Vol.9(4), pp.1289-1292
Main Author: Liu, Jing
Other Authors: Li, Guangbing , Liu, Dejie , Liu, Jun
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 1791-2997 ; E-ISSN: 1791-3004 ; DOI: 10.3892/mmr.2014.1928
Link: http://www.spandidos-publications.com/molecular medicine reports/9/4/1289
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: spandido10.3892/mmr.2014.1928
title: FH535 inhibits the proliferation of HepG2 cells via downregulation of the Wnt/β-catenin signaling pathway
format: Article
creator:
  • Liu, Jing
  • Li, Guangbing
  • Liu, Dejie
  • Liu, Jun
subjects:
  • Fh535
  • Wnt/Β-Catenin Pathway
  • Induced Nitric Oxide Synthase
  • Nitric Oxide
ispartof: Molecular Medicine Reports, 4/2014, Vol.9(4), pp.1289-1292
description: Hepatocellular carcinoma (HCC) is a primary cancer of the liver. Target therapy may improve prognosis of HCC. In the present study, we evaluated the inhibition of the Wnt/β-catenin pathway as a potential therapeutic approach. HepG2 cells were treated with the β-catenin inhibitor FH535. β-catenin protein expression was semi-quantitatively assessed using western blot analysis. Cell proliferation was examined with a 3-(4,5-dimethyl-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt (MTS) assay. The mRNA expression of nitric oxide synthase ( iNOS ) was detected by reverse transcription polymerase chain reaction. The Griess assay was used to determine nitric oxide (NO) concentration. FH535 inhibited the proliferation of HepG2 cells and decreased β-catenin protein expression. mRNA expression of iNOS, a target gene of the Wnt/β-catenin pathway, was decreased in FH535-treated HepG2 cells compared to the control group. NO production was also reduced by FH535. In conclusion, the β-catenin inhibitor FH535 may inhibit HCC cell proliferation via downregulation of the Wnt/β-catenin pathway. Thus, targeting this pathway may be useful in HCC therapy.
language: eng
source:
identifier: ISSN: 1791-2997 ; E-ISSN: 1791-3004 ; DOI: 10.3892/mmr.2014.1928
fulltext: fulltext
issn:
  • 1791-2997
  • 17912997
  • 1791-3004
  • 17913004
url: Link


@attributes
ID104000586
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid10.3892/mmr.2014.1928
sourceidspandido
recordidTN_spandido10.3892/mmr.2014.1928
sourceformatXML
sourcesystemPC
pqid1932462606
galeid415325175
display
typearticle
titleFH535 inhibits the proliferation of HepG2 cells via downregulation of the Wnt/β-catenin signaling pathway
creatorLiu, Jing ; Li, Guangbing ; Liu, Dejie ; Liu, Jun
ispartofMolecular Medicine Reports, 4/2014, Vol.9(4), pp.1289-1292
identifier
subjectFh535 ; Wnt/Β-Catenin Pathway ; Induced Nitric Oxide Synthase ; Nitric Oxide
descriptionHepatocellular carcinoma (HCC) is a primary cancer of the liver. Target therapy may improve prognosis of HCC. In the present study, we evaluated the inhibition of the Wnt/β-catenin pathway as a potential therapeutic approach. HepG2 cells were treated with the β-catenin inhibitor FH535. β-catenin protein expression was semi-quantitatively assessed using western blot analysis. Cell proliferation was examined with a 3-(4,5-dimethyl-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt (MTS) assay. The mRNA expression of nitric oxide synthase ( iNOS ) was detected by reverse transcription polymerase chain reaction. The Griess assay was used to determine nitric oxide (NO) concentration. FH535 inhibited the proliferation of HepG2 cells and decreased β-catenin protein expression. mRNA expression of iNOS, a target gene of the Wnt/β-catenin pathway, was decreased in FH535-treated HepG2 cells compared to the control group. NO production was also reduced by FH535. In conclusion, the β-catenin inhibitor FH535 may inhibit HCC cell proliferation via downregulation of the Wnt/β-catenin pathway. Thus, targeting this pathway may be useful in HCC therapy.
languageeng
source
version7
lds50peer_reviewed
links
openurl$$Topenurl_article
backlink$$Uhttp://www.spandidos-publications.com/molecular medicine reports/9/4/1289$$EView_this_record_in_Spandidos_Publications
openurlfulltext$$Topenurlfull_article
search
creatorcontrib
0LIU, JING
1LI, GUANGBING
2LIU, DEJIE
3LIU, JUN
titleFH535 inhibits the proliferation of HepG2 cells via downregulation of the Wnt/β-catenin signaling pathway
descriptionHepatocellular carcinoma (HCC) is a primary cancer of the liver. Target therapy may improve prognosis of HCC. In the present study, we evaluated the inhibition of the Wnt/β-catenin pathway as a potential therapeutic approach. HepG2 cells were treated with the β-catenin inhibitor FH535. β-catenin protein expression was semi-quantitatively assessed using western blot analysis. Cell proliferation was examined with a 3-(4,5-dimethyl-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt (MTS) assay. The mRNA expression of nitric oxide synthase ( iNOS ) was detected by reverse transcription polymerase chain reaction. The Griess assay was used to determine nitric oxide (NO) concentration. FH535 inhibited the proliferation of HepG2 cells and decreased β-catenin protein expression. mRNA expression of iNOS, a target gene of the Wnt/β-catenin pathway, was decreased in FH535-treated HepG2 cells compared to the control group. NO production was also reduced by FH535. In conclusion, the β-catenin inhibitor FH535 may inhibit HCC cell proliferation via downregulation of the Wnt/β-catenin pathway. Thus, targeting this pathway may be useful in HCC therapy.
subject
0FH535
1Wnt/β-catenin pathway
2induced nitric oxide synthase
3nitric oxide
general
010.3892/mmr.2014.1928
1D.A. Spandidos
2English
3Spandidios Publications (Spandidos Publications Ltd.)
sourceidspandido
recordidspandido10.3892/mmr.2014.1928
issn
01791-2997
117912997
21791-3004
317913004
rsrctypearticle
creationdate2014
addtitleMolecular Medicine Reports
searchscopespandidos
scopespandidos
lsr30VSR-Enriched:[galeid, pqid]
sort
titleFH535 inhibits the proliferation of HepG2 cells via downregulation of the Wnt/β-catenin signaling pathway
authorLiu, Jing ; Li, Guangbing ; Liu, Dejie ; Liu, Jun
facets
frbrgroupid1735236606831444546
frbrtype5
languageeng
creationdate2014
topic
0FH535
1Wnt/β-catenin pathway
2induced nitric oxide synthase
3nitric oxide
collectionSpandidios Publications (Spandidos Publications Ltd.)
prefilterarticles
rsrctypearticles
creatorcontrib
0Liu, Jing
1Li, Guangbing
2Liu, Dejie
3Liu, Jun
jtitleMolecular Medicine Reports
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0LIU
1LI
aufirst
0JING
1GUANGBING
2DEJIE
3JUN
au
0Liu, Jing
1Li, Guangbing
2Liu, Dejie
3Liu, Jun
atitleFH535 inhibits the proliferation of HepG2 cells via downregulation of the Wnt/β-catenin signaling pathway
jtitleMolecular Medicine Reports
date20144
risdate20144
volume9
issue4
spage1289
epage1292
pages1289-1292
issn1791-2997
eissn1791-3004
formatjournal
genrearticle
ristypeJOUR
abstractHepatocellular carcinoma (HCC) is a primary cancer of the liver. Target therapy may improve prognosis of HCC. In the present study, we evaluated the inhibition of the Wnt/β-catenin pathway as a potential therapeutic approach. HepG2 cells were treated with the β-catenin inhibitor FH535. β-catenin protein expression was semi-quantitatively assessed using western blot analysis. Cell proliferation was examined with a 3-(4,5-dimethyl-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt (MTS) assay. The mRNA expression of nitric oxide synthase ( iNOS ) was detected by reverse transcription polymerase chain reaction. The Griess assay was used to determine nitric oxide (NO) concentration. FH535 inhibited the proliferation of HepG2 cells and decreased β-catenin protein expression. mRNA expression of iNOS, a target gene of the Wnt/β-catenin pathway, was decreased in FH535-treated HepG2 cells compared to the control group. NO production was also reduced by FH535. In conclusion, the β-catenin inhibitor FH535 may inhibit HCC cell proliferation via downregulation of the Wnt/β-catenin pathway. Thus, targeting this pathway may be useful in HCC therapy.
pubD.A. Spandidos
doi10.3892/mmr.2014.1928